T1	intervention 60 69	vitamin D
T2	eligibility 530 568	Newly diagnosed breast cancer patients
T3	control 631 638	placebo
T5	total-participants 863 865	83
T6	total-participants 887 889	80
T7	intervention-participants 911 913	43
T8	control-participants 936 938	37
T9	outcome 1104 1140	percent changes of either Ki67 index
T10	outcome 1171 1174	CC3
T11	outcome 1208 1249	Serum 25-hydroxyvitamin D (25-OHD) levels
T12	outcome 1330 1345	Adverse effects
T13	iv-cont-mean 1142 1146	1.6%
T14	cv-cont-mean 1151 1156	16.7%
T15	iv-cont-mean 1176 1183	- 55.9%
T16	cv-cont-mean 1190 1195	45.9%
T17	iv-cont-mean 1292 1301	62 nmol/L
T18	cv-cont-mean 1306 1316	246 nmol/L
T4	outcome-Measure 710 762	elative change in proliferation (Ki67) and apoptosis
